IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that results from the initial analysis of the ...
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 ...
Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333 MINDACT was supported by ...
Data from the MINDACT trial revealed that among women with luminal breast cancers (hormone receptor–positive, HER2-negative by local pathology) with a high clinical risk and low genomic risk, those ...
IRVINE, Calif., Aug. 25, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, announced the publication of multi-country cost analyses from the landmark MINDACT ...
IRVINE, Calif. and AMSTERDAM, May 29, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced new data from MINDACT, the prospective randomized ...
Barcelona, Spain: Women with small, low grade, well-defined breast tumours and a genetic profile that shows they are at low risk of the cancer metastasising have only a 1.4% risk of the cancer ...
LUGANO-MADRID, Sept. 3, 2017 - Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. (1) ...
IRVINE, Calif. & AMSTERDAM, April 30, 2026--(BUSINESS WIRE)--Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results